Loading…
Loading…
TNON does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TNON and 80,000+ other tickers.
See exactly how TNON's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TNON and 80,000+ other tickers.
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
LOS GATOS, CA / ACCESS Newswire / August 24, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). On February 25, 2026, the Company received a letter from the Listing Qualifications staff of Nasdaq (the "Staff") notifying it that, for the prior 30 consecutive business days, the closing bid price of the Company's common stock had been below the $1.00 per share minimum required under the Bid Price Rule.
Tenon Medical, Inc. (TNON) Q2 2026 Earnings Call Transcript
~ Second Quarter 2026 Revenue of $1.3 Million, a 127% Increase Compared to Prior Year ~ ~ Second Quarter Gross Profit of $0.8 Million, a 232% Increase Compared to Prior Year; Gross Margin of 64% ~ ~ Received FDA 510(k) Clearance for Updated Catamaran® SI Joint Fusion System ~ ~ Physician and Distributor Training Events Increased 98% in 1H 2026 Compared to 2H 2025, Supporting Record Monthly Case Volume in July 2026 ~ ~ Closed $4.2 Million Public Offering Subsequent to Quarter End ~ LOS GATOS, CA / ACCESS Newswire / August 13, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today reported financial results for the second quarter ended June 30, 2026. Financial Results and Business Updates Second Quarter 2026 Results: Second quarter revenue of $1.3 million, an increase of 127% compared to $0.6 million in the second quarter of 2025.
LOS GATOS, CA / ACCESS Newswire / August 6, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced a 1-for-35 reverse stock split of the Company's issued and outstanding common stock. The reverse stock split will become effective at 12:01, Eastern Time, on August 10, 2026, prior to the commencement of trading on the Nasdaq Capital Market.
LOS GATOS, CA / ACCESS Newswire / July 30, 2026 / Tenon Medical, Inc. (NASDAQ:TNON)("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced plans to release financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 13, 2026. The Company will also hold a conference call on the same day at 4:30 p.m.